

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements is true about the design of the Phase III SOLO-1 trial that led to the FDA approval of olaparib as maintenance therapy for patients with advanced ovarian cancer (OC) after response to first-line platinum-based chemotherapy?

 - a. All trial participants received maintenance olaparib for 36 months or until objective radiological disease progression
 - b. Only patients with deleterious or suspected deleterious germline or somatic BRCA mutations were eligible**
2. On the basis of recently published results from the Phase III PRIMA study, niraparib was recently FDA approved for patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in which of the following settings?

 - a. As maintenance therapy for patients who are in a complete or partial response to first-line platinum-based chemotherapy regardless of homologous recombination deficiency (HRD) status**
 - b. In combination with bevacizumab as first-line maintenance therapy for patients who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with HRD-positive status
3. A progression-free survival subgroup analysis presented at the 2019 ESMO meeting evaluating outcomes for patients who received niraparib on the PRIMA study demonstrated the highest benefit in which of the following patient populations?

 - a. Those with BRCA-mutated/HRD disease**
 - b. Those with BRCA wild-type/HRD disease
 - c. Those with homologous recombination proficient disease
4. On the basis of recently presented results from the Phase III PAOLA-1 trial, the combination of bevacizumab with which of the following PARP inhibitors was FDA approved as first-line maintenance therapy for patients with advanced OC who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with HRD-positive status?

 - a. Veliparib
 - b. Rucaparib
 - c. Niraparib
 - d. Olaparib**